Christopher J. Kirk

This profile gathers the share dealings of Christopher J. Kirk in Kezar Life Sciences, Inc. In total, 5 filings cover trades dated from 9 August 2019 to 20 July 2023.

Purchases make up the whole of the open-market record (3 purchases, €133k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 option exercises.

In size, the median ticket on the buying side is €22k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 24 July 2023 came the latest disclosure, an option exercise for €40k in Kezar Life Sciences, Inc. The last insider purchase was made public on 5 February 2020, 2,468 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.